Abstract: The present invention relates to the radiolabelled compound of enantiomer (R,R) of 5-fluoro-3-4(-phenylpiperidin-1-yl)-1,2,3,4-tetrahydronaphthalen-2-ol, and to this compound for use thereof in an in vivo diagnosis method, in particular of a cholinergic neurodegenerative disease selected for example from the group formed by Alzheimer's disease, dysmnesia, learning disability, schizophrenia, cognitive dysfunction, hyperactivity disorder, anxiety neurosis, depression, analgesia and Parkinson's disease.

Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases.

Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.

Abstract: The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases

Abstract: The present invention relates to 18-Fluor radiolabeled macrocyclic quinazoline compounds, which are suitable as positron emission tomography (PET) tracers for imaging epidermal growth factor receptors (EGFR), and their use in in vivo diagnosis, preclinical and clinical tumour imaging, patient stratification on the basis of mutational status of EGFR, and assessing tumour response to therapeutic treatments. The present invention also describes precursor compounds and methods of preparing the radiotracers. The invention is relevant to any cancer that is influenced or driven by deregulated EGFR, such as, but not limited to, non-small cell lung cancer (NSCLC), pancreatic, hepatocellular, oesophageal, gastric, colorectal, prostate, cervical, renal, ovarian, breast cancers, head and neck squamous cell carcinoma, and malignant glioma.

Abstract: A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN? groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.

Abstract: A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN? groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.